Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Ocular Therapeutix, Inc.NASDAQ: OCUL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$84.55M, compared with -$60.09M a year earlier. Trailing-twelve-month EBITDA was -$274.24M.

Context

  • EBITDA amounted to 482.0% of revenue in FY2025, up 205.6 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -$281.38M (-12.6%) for the fiscal year ending Dec 2026, a step up from the -41.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$84.55M-39.6% QoQ
Last fiscal yearDec 2025
-$249.78M-41.8% YoY
LTMMar 2026
-$274.24M-55.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.7%-32.6%+8.2 pp
1 year-41.8%-12.6%+29.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(249.78M) USD
Year-over-year change
-41.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -55.5% is the 7th highest of 10, against a peer median of -18.0%.
  • EBITDA amounts to 527.0% of revenue for OCUL, versus a peer median of 730.2%.
OCUL Competitors
EBITDA for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$742M USD+61.3%-3.6%13.9%
HROWHarrow Health, Inc.LTM Mar 2026$31.47M USD+78.4%—11.7%
STAASTAAR Surgical CompanyLTM Apr 2026-$4.11M USD+87.8%—1.4%
SGPSpyGlass Pharma, Inc. Common StockFY2025-$39.26M USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.08M USD-482.8%—18634.1%
OCGNOcugen, Inc.LTM Mar 2026-$64.18M USD-19.1%—1437.5%
OCSOculis Holding AGLTM Mar 2026-CHF 94.13M CHF+7.5%—18676.3%
GKOSGlaukos CorporationLTM Jun 2026-$140.99M USD-195.0%—23.0%
KODKodiak Sciences Inc.LTM Sep 2026-$225.15M USD-18.0%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$260.06M USD-79.4%—3415.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$274.24M USD-55.5%—527.0%
Peer median (excluding OCUL) —-18.0%-3.6%730.2%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.